Last reviewed · How we verify
BTDS
At a glance
| Generic name | BTDS |
|---|---|
| Sponsor | Mundipharma Research Limited |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Butrans for Treatment of Restless Legs Syndrome (PHASE4)
- The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers (PHASE1)
- A Study to Characterize the Pharmacokinetics and Tolerability of Buprenorphine Patches in Children With Moderate to Severe Mouth Pain (PHASE1, PHASE2)
- Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children (PHASE3)
- Postoperative Analgesia With Buprenorphine for Postoperative Pain Control and Quality of Life After Spinal Surgery (PHASE4)
- An Assessment of Buprenorphine Transdermal Delivery System (BTDS) Patch Adhesion (PHASE1)
- Bioequivalence and Adhesion Comparison of Buprenorphine Patches (PHASE1)
- Norspan Transdermal Patches Study in Osteoarthritis Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BTDS CI brief — competitive landscape report
- BTDS updates RSS · CI watch RSS
- Mundipharma Research Limited portfolio CI